EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Histone H3.3 mutation in giant cell tumor of bone: an update in pathology

Hidetaka Yamamoto, Shin Ishihara, Yu Toda, Yoshinao Oda

Medical Molecular Morphology · 2020-03 · 53 (1) · 1-6

DOI: 10.1007/s00795-019-00238-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Molecular Morphology, online erschienen am 20.11.2019. Verfasst von Hidetaka Yamamoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. hid…. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic, Mutation. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Giant cell tumor of bone (GCTB) is a locally aggressive bone tumor that frequently shows local recurrence and occasionally shows malignant transformation to high-grade sarcoma. Histologically, conventional GCTB is composed mainly of three types of cells: mononuclear neoplastic cells with an osteoblastic precursor phenotype, mononuclear histiocytic cells, and osteoclast-like multinucleated giant cells. These cells interact with each other via the RANKL-RANK axis and other mechanisms for tumor formation. The vast majority of GCTBs were recently revealed to harbor H3F3A p.G34W mutation, and a minor subset have H3F3A p.G34L, p.G34M, p.G34R, or p.G34V mutation. H3.3 G34W mutant-specific immunohistochemistry is a highly sensitive and specific surrogate marker for H3F3A p.G34W mutation in GCTB and thus useful for differential diagnoses of histological mimics. H3.3 mutant-specific immunohistochemistry has also contributed to the understanding of the bone-forming ability of neoplastic cells of GCTB and the remarkable new bone formation after treatment with denosumab, an inhibitor of RANKL. In primary and secondary malignant GCTBs, the H3F3A gene allele can be preserved or lost with malignant transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene Expression Regulation, NeoplasticMutationBone Density Conservation AgentsBone NeoplasmsDenosumabDisease ProgressionGiant Cell Tumor of BoneHistiocytesHistonesHumansImmunohistochemistryNeoplasm GradingNeoplasm Recurrence, LocalOsteoblastsOsteoclastsRANK LigandReceptor Activator of Nuclear Factor-kappa BSarcoma

Stichwörter der Autor:innen

DenosumabGiant cell tumor of boneH3F3AHistone H3.3ImmunohistochemistryMutation

Substanzen

Bone Density Conservation AgentsHistonesRANK LigandReceptor Activator of Nuclear Factor-kappa BTNFRSF11A protein, humanTNFSF11 protein, humanDenosumab

Autor:innen und Institutionen

  • Department of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. hidetaka@surgpath.med.kyushu-u.ac.jp.
  • Department of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Zitieren

APA

Yamamoto, H., Ishihara, S., Toda, Y., & Oda, Y. (2020). Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Medical Molecular Morphology, 53(1), 1-6. https://doi.org/10.1007/s00795-019-00238-1

Vancouver

Yamamoto H, Ishihara S, Toda Y, Oda Y. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Medical Molecular Morphology. 2020;53(1):1-6. doi:10.1007/s00795-019-00238-1

BibTeX
@article{Yamamoto2020,
  author = {Yamamoto, Hidetaka and Ishihara, Shin and Toda, Yu and Oda, Yoshinao},
  title = {Histone H3.3 mutation in giant cell tumor of bone: an update in pathology},
  journal = {Medical Molecular Morphology},
  year = {2020},
  volume = {53},
  number = {1},
  pages = {1--6},
  doi = {10.1007/s00795-019-00238-1}
}
Kostenlos starten →